Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Viking Therapeutics (VKTX) EBIT: 2014-2024

Historic EBIT for Viking Therapeutics (VKTX) over the last 11 years, with Dec 2024 value amounting to -$150.9 million.

  • Viking Therapeutics' EBIT fell 169.62% to -$98.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$274.8 million, marking a year-over-year decrease of 105.15%. This contributed to the annual value of -$150.9 million for FY2024, which is 49.68% down from last year.
  • According to the latest figures from FY2024, Viking Therapeutics' EBIT is -$150.9 million, which was down 49.68% from -$100.8 million recorded in FY2023.
  • Viking Therapeutics' EBIT's 5-year high stood at -$42.7 million during FY2020, with a 5-year trough of -$150.9 million in FY2024.
  • For the 3-year period, Viking Therapeutics' EBIT averaged around -$107.4 million, with its median value being -$100.8 million (2023).
  • Data for Viking Therapeutics' EBIT shows a maximum YoY crashed of 49.68% (in 2024) over the last 5 years.
  • Over the past 5 years, Viking Therapeutics' EBIT (Yearly) stood at -$42.7 million in 2020, then tumbled by 30.52% to -$55.7 million in 2021, then dropped by 26.35% to -$70.4 million in 2022, then plummeted by 43.31% to -$100.8 million in 2023, then plummeted by 49.68% to -$150.9 million in 2024.